Related Experiment Video
Updated: Aug 7, 2026

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
Selective inhibition of the human tie-1 promoter with triplex-forming oligonucleotides targeted to Ets binding sites
Peter W Hewett1, Emma L Daft, Charles A Laughton
1Department of Vascular and Reproductive Biology, Institute for Biomedical Research, The Medical School, University of Birmingham, Edgbaston, Birmingham, UK. p.w.hewett.@bham.ac.uk
Abstract:
The Tie receptors (Tie-1 and Tie-2/Tek) are essential for angiogenesis and vascular remodeling/integrity. Tie receptors are up-regulated in tumor-associated endothelium, and their inhibition disrupts angiogenesis and can prevent tumor growth as a consequence. To investigate the potential of anti-gene approaches to inhibit tie gene expression for anti-angiogenic therapy, we have examined triple-helical (triplex) DNA formation at 2 tandem Ets transcription factor binding motifs (designated E-1 and E-2) in the human tie-1 promoter. Various tie-1 promoter deletion/mutation luciferase reporter constructs were generated and transfected into endothelial cells to examine the relative activities of E-1 and E-2. The binding of antiparallel and parallel (control) purine motif oligonucleotides (21-22 bp) targeted to E-1 and E-2 was assessed by plasmid DNA fragment binding and electrophoretic mobility shift assays. Triplex-forming oligonucleotides were incubated with tie-1 reporter constructs and transfected into endothelial cells to determine their activity. The Ets binding motifs in the E-1 sequence were essential for human tie-1 promoter activity in endothelial cells, whereas the deletion of E-2 had no effect. Antiparallel purine motif oligonucleotides targeted at E-1 or E-2 selectively formed strong triplex DNA (K(d) approximately 10(-7) M) at 37 degrees C. Transfection of tie-1 reporter constructs with triplex DNA at E-1, but not E-2, specifically inhibited tie-1 promoter activity by up to 75% compared with control oligonucleotides in endothelial cells. As similar multiple Ets binding sites are important for the regulation of several endothelial-restricted genes, this approach may have broad therapeutic potential for cancer and other pathologies involving endothelial proliferation/dysfunction.
Insights
Researchers explored inhibiting Tie-1 gene expression using triplex DNA to block tumor angiogenesis. Targeting the E-1 motif in the tie-1 promoter significantly reduced gene activity, showing potential for anti-angiogenic cancer therapy.
Area of Science:
- Molecular biology
- Gene regulation
- Cancer research
Background:
- Tie receptors (Tie-1, Tie-2/Tek) are crucial for angiogenesis and vascular integrity.
- These receptors are upregulated in tumor endothelium, making them targets for anti-angiogenic therapy.
- Inhibiting Tie receptors can disrupt tumor angiogenesis and growth.
Purpose of the Study:
- To investigate anti-gene strategies targeting the human tie-1 promoter for anti-angiogenic therapy.
- To examine triple-helical DNA formation at Ets transcription factor binding motifs (E-1, E-2) in the tie-1 promoter.
- To assess the therapeutic potential of inhibiting tie-1 gene expression.
Main Methods:
- Generated and transfected tie-1 promoter deletion/mutation luciferase reporter constructs into endothelial cells.
- Assessed oligonucleotide binding to Ets motifs (E-1, E-2) using plasmid DNA fragment binding and electrophoretic mobility shift assays.
- Transfected triplex-forming oligonucleotides with tie-1 reporter constructs to determine their inhibitory activity.
Main Results:
- The Ets binding motifs in the E-1 sequence were essential for tie-1 promoter activity; E-2 was not.
- Antiparallel purine motif oligonucleotides selectively formed strong triplex DNA at E-1 and E-2.
- Triplex DNA targeting E-1 inhibited tie-1 promoter activity by up to 75% in endothelial cells.
Conclusions:
- The E-1 Ets binding motif is critical for human tie-1 promoter activity.
- Triple-helical DNA formation targeting the E-1 motif is a viable strategy to inhibit tie-1 gene expression.
- This anti-gene approach holds therapeutic potential for cancers and other diseases involving endothelial dysfunction.

